BTIG analyst Mark Massaro maintained a Buy rating on Adaptive Biotechnologies (NASDAQ:ADPT) Corp on Thursday, setting a price target of $60, which is approximately 60.60% above the present share price of $37.36.
Massaro expects Adaptive Biotechnologies Corp to post earnings per share (EPS) of -$0.29 for the third quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Adaptive Biotechnologies, with an average price target of $57.5.
The analysts price targets range from a high of $60 to a low of $55.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $38.44 million and a net profit of -$41.28 million. The company's market cap is $5.24 billion.
According to TipRanks.com, BTIG analyst Mark Massaro is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 25.3% and a 62.57% success rate.
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.